[1]

Ding YN, Chen XG, Zhang QJ, et al. Historical trends in breast cancer among women in China from age-period-cohort modeling of the 1990−2015 breast cancer mortality data[J/OL]. BMC Public Health, 2020, 20(1): 1280[2019-06-08]. https://www.ncbi.nlm.nih.gov/pmc/journals/63. DOI: 10.1186/s12889-020-09375-0.
[2] Sun Y, Wei W, Yang HW, et al.  Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2013, 40(3): 450-463.   doi: 10.1007/s00259-012-2279-5
[3] Huppe AI, Mehta AK, Brem RF.  Molecular breast imaging: A comprehensive review[J]. Semin Ultrasound CT MR, 2018, 39(1): 60-69.   doi: 10.1053/j.sult.2017.10.001
[4] Coates AS, Winer EP, Goldhirsch A, et al.  Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J]. Ann Oncol, 2015, 26(8): 1533-1546.   doi: 10.1093/annonc/mdv221
[5] Meissnitzer T, Meissnitzer MW, Seymer A, et al.  Relative uptake factor of invasive ductal breast cancer in breast-specific gamma imaging as a surrogate parameter for sub-typing[J]. Anticancer Res, 2015, 35(10): 5671-5677.
[6] Tan H, Zhang HW, Yang WG, et al.  Breast-specific gamma imaging with Tc-99m-sestamibi in the diagnosis of breast cancer and its semiquantitative index correlation with tumor biologic markers, subtypes, and clinicopathologic characteristics[J]. Nucl Med Commun, 2016, 37(8): 792-799.   doi: 10.1097/MNM.0000000000000518
[7] Yoon HJ, Kim Y, Chang KT, et al.  Prognostic value of semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer[J]. Ann Nucl Med, 2015, 29(7): 553-560.   doi: 10.1007/s12149-015-0977-3
[8] Goldsmith SJ, Parsons W, Guiberteau MJ, et al.  SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0[J]. J Nucl Med Technol, 2010, 38(4): 219-224.   doi: 10.2967/jnmt.110.082271
[9] Lee SJ, Choi YY, Kim C, et al.  Correlations between tumor to background ratio on breast-specific gamma imaging and prognostic factors in breast cancer[J]. J Korean Med Sci, 2017, 32(6): 1031-1037.   doi: 10.3346/jkms.2017.32.6.1031
[10] Hammond ME, Hayes DF, Dowsett M, et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-2795.   doi: 10.1200/JCO.2009.25.6529
[11] Inda MA, Blok EJ, Kuppen PJK, et al.  Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer[J]. Mol Cancer Ther, 2020, 19(2): 680-689.   doi: 10.1158/1535-7163.MCT-19-0318
[12] Gradishar WJ, Anderson BO, Balassanian R, et al.  NCCN guidelines insights: breast cancer, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(4): 433-451.   doi: 10.6004/jnccn.2017.0044
[13] Narayanan D, Berg WA.  Dedicated breast gamma camera imaging and breast PET: current status and future directions[J]. PET Clin, 2018, 13(3): 363-381.   doi: 10.1016/j.cpet.2018.02.008
[14] Sanli Y, Kuyumcu S, Ozkan ZG, et al.  Increased FDG uptake in breast cancer is associated with prognostic factors[J]. Ann Nucl Med, 2012, 26(4): 345-350.   doi: 10.1007/s12149-012-0579-2
[15] Kim J, Yoo SW, Kang SR, et al.  Prognostic significance of metabolic tumor volume measured by 18F-FDG PET/CT in operable primary breast cancer[J]. Nucl Med Mol Imaging, 2012, 46(4): 278-285.   doi: 10.1007/s13139-012-0161-9
[16] Papantoniou V, Christodoulidou J, Papadaki E, et al.  Uptake and washout of 99mTcV-dimercaptosuccinic acid and 99mTc-sestamibi in the assessment of histological type and grade in breast cancer[J]. Nucl Med Commun, 2002, 23(5): 461-467.   doi: 10.1097/00006231-200205000-00006
[17] Papantoniou VJ, Souvatzoglou MA, Valotassiou VJ, et al.  Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer[J]. Breast Cancer Res, 2004, 6(2): R56-R62.   doi: 10.1186/bcr751
[18] Kim S, Plemmons J, Hoang K, et al.  Breast-Specific gamma imaging versus MRI: comparing the diagnostic performance in assessing treatment response after neoadjuvant chemotherapy in patients with breast cancer[J]. AJR Am J Roentgenol, 2019, 212(3): 696-705.   doi: 10.2214/AJR.17.18930
[19] Cwikla JB, Buscombe JR, Kolasinska AD, et al.  Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer[J]. Anticancer Res, 1999, 19(3B): 2299-2304.
[20] Tadwalkar RV, Rapelyea JA, Torrente J, et al.  Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade[J]. Br J Radiol, 2012, 85(1014): e212-e216.   doi: 10.1259/bjr/34392802
[21] Senkus E, Kyriakides S, Ohno S, et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl 5): Sv8-30.   doi: 10.1093/annonc/mdv298